By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Otsuka Pharmaceutical Co., Ltd. 

2-9 Kanda Tsukasa-cho
Chiyoda-ku
Tokyo    101-8535  Japan
Phone: 03-3292-0021 Fax:


SEARCH JOBS


Industry
Pharmaceutical






Company News
Efficacy Results Of Otsuka Pharma’s Delamanid (Deltyba) For Extensively Drug-Resistant Tuberculosis (XDR-TB) Published In The New England Journal of Medicine 7/16/2015 11:12:48 AM
Otsuka Pharma, H. Lundbeck A/S (LUN.CO) Beat Competitors With FDA Approval of Schizophrenia Drug 7/13/2015 6:38:10 AM
Otsuka Pharmaceutical Co., Ltd.’s JINARC The First-Ever Treatment Approved In Europe For Adults Living With ADPKD, A Chronic Genetic Kidney Disease 5/27/2015 10:57:58 AM
Otsuka Pharmaceutical Co., Ltd. Release: Pre-Filled Dual-Chamber Syringe For Abilify Maintena (Aripiprazole) Prolonged-Release Suspension For Injection, Used In The Treatment Of Schizophrenia, Receives Positive CHMP Opinion (Approval In EU) 3/30/2015 12:59:23 PM
Otsuka Pharmaceutical Co., Ltd. Release: First-Ever Treatment Approved In Canada For Adults Living With ADPKD, A Life-Threatening Kidney Disease 3/2/2015 6:59:19 AM
Otsuka Pharmaceutical Co., Ltd. Release: CHMP Recommends Jinarc (Tolvaptan) For Approval In EU: The First Pharmaceutical Treatment For Autosomal Dominant Polycystic Kidney Disease (Adpkd) 2/27/2015 8:22:32 AM
Otsuka Pharmaceutical Co., Ltd. Release: First-Ever Treatment Approved In Canada For Adults Living With ADPKD, A Life-Threatening Kidney Disease 2/27/2015 6:47:35 AM
GW Pharmaceuticals (GWPH) And Otsuka Pharmaceutical Co., Ltd. Announce Results In First Of Three Sativex® Phase 3 Cancer Pain Trials 1/8/2015 8:34:21 AM
Otsuka Pharmaceutical Co., Ltd. And H. Lundbeck A/S (LUN.CO)’s Brexpiprazole Demonstrates Statistically Significant Effects In New Phase 3 Studies In Adult Patients With Schizophrenia Presented At The American College Of Neuropsychopharmacology Annual Meeting 12/11/2014 7:27:03 AM
Otsuka Pharmaceutical Co., Ltd. And H. Lundbeck A/S (LUN.CO) Present Phase 3 Data On Brexpiprazole As Adjunctive Therapy In Adult Patients With Major Depression At The American College Of Neuropsychopharmacology Annual Meeting 12/10/2014 10:29:43 AM
12345678910...
//-->